# Recognition and Measurement of Internally Generated Intangible Assets ## (a) Lifecycle Diagram: Research vs. Development Stages The lifecycle of internally generated intangible assets in innovation-driven firms typically follows these phases: **Research Phase:** Activities aimed at gaining new knowledge without a specific commercial objective. Costs are expensed as incurred. **Development Phase:** Application of research findings to a plan or design for new or improved products/processes before commercial production. Costs may be capitalized if certain criteria are met. A diagram representation: ``` |---------------------|-------------------------|----------------------|-----------------------| | Research Phase | Development Phase | Testing/Prototype | Commercialization | | (Costs expensed) | (Costs eligible for | (Further development | (Asset in use, | | | capitalization if | or initial production| amortization begins) | | | criteria are met) | costs) | | |---------------------|-------------------------|----------------------|-----------------------| ``` *Alt text: Diagram showing sequential phases: Research (expensed), Development (potentially capitalized), Testing, Commercialization (amortization).* ## (b) Capitalization Eligibility Decision Matrix A decision matrix for whether costs can be capitalized under IAS 38 or similar standards might look like this: | Criteria for Capitalization | Met? (Y/N) | Action | |-----------------------------------------|------------|-----------------| | Technical feasibility | | | | Intention to complete and use/sell | | | | Ability to use/sell | | | | Probable future economic benefits | | | | Availability of resources | | | | Reliable measurement of costs | | | | **All criteria met?** | | Capitalize | | **Any criteria not met?** | | Expense | *Alt text: Table showing six capitalization criteria; all must be met for capitalization, otherwise expense.* ## (c) Intangible Asset Amortization Schedule Table Assume an intangible asset is capitalized at \$100,000, with a 5-year useful life and straight-line amortization, no residual value. The amortization schedule would be: | Year | Opening Balance | Amortization Expense | Closing Balance | |------|----------------|----------------------|----------------| | 1 | \$100,000 | \$20,000 | \$80,000 | | 2 | \$80,000 | \$20,000 | \$60,000 | | 3 | \$60,000 | \$20,000 | \$40,000 | | 4 | \$40,000 | \$20,000 | \$20,000 | | 5 | \$20,000 | \$20,000 | \$ | *Alt text: Table showing five-year straight-line amortization from \$100,000 to \$.* ## (d) Financial Statement Distortion Risks **With Capitalization:** Capitalizing development costs increases assets and defers expense recognition. This can inflate profits and assets in the short term, possibly overstating ROI and equity. If future benefits do not materialize, future write-downs or impairment losses may distort future profits. **Without Capitalization (Immediate Expensing):** Expensing all R&D costs immediately understates current profits and assets, potentially misrepresenting a firm’s value and performance if the expenditures are likely to generate future benefits. This can make the company appear less profitable and less valuable than it actually is. **Conclusion:** Both approaches carry risks of financial statement distortion. Capitalization may overstate, while immediate expensing may understate, the company's financial position and performance. Proper judgment and disclosure are essential to mitigate these risks.